|Videos|October 11, 2021
Dr. Matulewicz on smoking status data in genitourinary cancer trials
Author(s)Urology Times staff
“In short, there's a ton of missed opportunity to see how smoking affects treatments, especially in trial patients, and even in our patients that are in our clinics,” says Richard Matulewicz, MD, MS.
Advertisement
In this video, Richard Matulewicz, MD, MS, discusses the background and findings of the study, “Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials,” presented recently at the 2021 American Urological Association Annual Meeting. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
